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Brief Communication
A  U n i q u e l y  S e l e c t i v e  I n h i b i t o r  o f  t h e  M a m m a l i a n  F e t a l  
N e u r o m u s c u l a r  N i c o t i n i c  A c e t y l c h o l i n e  R e c e p t o r
Russell W. Teichert,1 Jean Rivier,2 Josep Torres,2 John Dykert,2 Charleen Miller,2 and Baldomero M. Olivera1
'Department of Biology, University of Utah, Salt lake City, Utah 84112, and 2Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, 
La Jolla, California 92037
We have purified and characterized a novel conotoxin from the venom of C o n u s  o b s c u r u s , which has the unique property of selectively and 
potently inhibiting the fetal form of the mammalian neuromuscular nicotinic acetylcholine receptor (nAChR) (alj31yc>-subunits). 
Although this conotoxin, aA-conotoxin OIVB (aA-OIVB), is a  high-affinity antagonist (IC50 of 56 n\t) of the fetal muscle nAChR, it has 
>  1800-fold lower affinity for the adult muscle nAChR ( a l  j31 efi-subunits) and virtually no inhibitory activity at a high concentration on 
various neuronal nAChRs (IC50 >  100 f i m in all cases). The peptide (amino acid sequence, CCGVONAACPOCVCNKTCG), with three 
disulfide bonds, has been chemically synthesized in a biologically active form. Although the neuromuscular nAChRs are perhaps the most 
extensively characterized of the receptors/ion channels of the nervous system, the precise physiological roles of the fetal form of the 
muscle nAChR are essentially unknown. aA-OIVB is a  potentially important tool for delineating the functional roles of a l  j31 yfi receptors 
in normal development, as well as in various adult tissues and in pathological states. In addition to its potential as a research tool, 
aA-OIVB may have some direct biomedical applications.
K e y  w o r d s :  fetal; muscle; nAChR; acetylcholine; inhibitor; receptor
In tro d u c tio n
The discovery o f a -bungaro tox in  approxim ately four decades 
ago, which provided a m eans o f isolating the nicotinic acetylcho­
line receptor (nAChR) from  the electric ray, was a sem inal dis­
covery in the history of m olecular neuroscience (C hang and  Lee, 
1963). As a consequence o f tha t discovery, the nAChR at the 
neurom uscular junction  was extensively characterized. It is 
know n to form a heteropentam er consisting o f two a  1-subunits, 
single j31- and  6-subunits, and either a y- o r an e-subunit 
(M ishina et al., 1986; Changeux et al., 1992). In the fetal stage of 
developm ent, m am m alian m uscle cells express nAChRs that con­
sist o fa lj3 1  -yS-subunits, b u t, in late gestation, the -y-subunit is 
replaced with the e-subunit (alj31 eS-subunits) (M ishina et al., 
1986; W itzem ann et al., 1987, 1989). The heteropentam eric re­
ceptor form s an ion channel gated by the neuro transm itter ace­
tylcholine, which opens the channel after b ind ing  at both  the a/d  
and  a /y  o r a /e  interfaces o f the receptor (B lount and  Merlie, 
1989).
A lthough the -y-subunit o f the neurom uscular nAChR is re­
placed by the e-subunit in m am m alian m uscle during late gesta­
tion, there are instances o f fetal m uscle nAChR expression in 
adult m am m alian  tissues. U nder norm al physiological condi-
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tions, expression o f the -y-subunit occurs in the thym us (M arx et 
al., 1989; N avaneetham  et al., 2001) and  extraocular muscle fibers 
(I lo r to n e ta l ., 1993). N icotinic receptors with y-subunits are also 
ectopically expressed under a num ber o f pathological conditions; 
the y -subun it is expressed in denervated m uscle (C u and  Hall, 
1988; W itzem ann et al., 1989) and  m uscle tissue associated with 
various neurogenic and  myogenic disorders (G attenloehner et 
al., 2002). It is also expressed in rhabdom yosarcom a, a pediatric 
soft-tissue cancer (G attenloehner et al., 1998, 1999). Tn these var­
ious tissues, the physiological roles o f the fetal m uscle nAChR are 
essentially unknow n. A ligand that could serve as a tool to eluci­
date the physiological roles o f the fetal m uscle nAChR w ould be 
of considerable value to neuroscientists. However, the character­
ized inhibitors o f the m uscle nAChR do no t include ligands with 
such b ind ing  specificity.
W e report the purification and  characterization o f a peptide 
toxin from  the venom o f the m arine cone snail, Conns obsatnts, 
that selectively inhibits the m am m alian fetal m uscle nAChR 
(alj31 yS-subunits) with significantly higher affinity than the 
m am m alian adu lt m uscle nAChR ( a l  j31 eS-subunits). This pep­
tide, which we nam ed aA -conotox in  OIVB (aA-OTVB), is 
un ique with respect to  its selectivity. This peptide toxin does no t 
block any of the neuronal nAChR subtypes tested. The specificity 
o f aA-OIVB for the fetal m uscle nAChR m akes it an im portan t 
tool for delineating the functional roles o f a l  j31 yS receptors and 
further elucidating where and  when these receptors m ay be 
present.
M aterials an d  M ethods
Biological specimens. C. obscurus specimens were collected near Oahu, 
Hawaii, by Ray McKinsey and Wes Thorsson (Hawaiian Malacological
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Society, Honolulu, HI). The majority of the specimens were found under 
flat coral slabs at depths of 60-90 feet
Purification of native peptide aA-OIVB. Venom milked from C. obscu­
rus (5 /ul) as described previously (Hopkins e ta l, 1995) was diluted to 25 
/ul with 15% B70 [70% acetonitrile (ACN) in 0.1% trifluoroacetic acid 
(TFA)j and applied to a Cs HPI.C column [2.1 X 100 mm; Brownlee 
Aquapore RP-300 (PerkinElmer Life Sciences, Emeryville, CA)) main­
tained at 40°C. The peptide designated aA-OIVB was obtained from the 
absorbance peak marked by an arrow in Figure 1A by fractionation of 50 
/ul aliquots on the analytical column eluted with gradients of ACN in
0.1% TFA at 40°C, as described previously (Teichert et al, 2004). The 
peptide was reapplied to the same Cs column and eluted with the same 
buffer system using the gradient shown in Figure 1 B, leading to further 
purification.
Peptide synthesis. The peptide aA-OIVB was synthesized automatically 
on a methylbenzydrylamine resin (2 g, 0.76 mM/g) (Stewart et al, 1976). 
The following side chain-protected t-butoxycarbonyl (Boc)-amino acids 
were used: hydroxyproline-benzyl [Hypro(Bzl)); cysteine-4-methoxyben- 
zyl; asparagine-xanthyl [Asn(Xan)); and lysine-2-chorobenzyloxycarbonyl. 
N ',-Boc-amino acids were coupled in 2.5-fold excess via 1,3-diisopropylcar- 
bodiimide in dichloromethane (DCM) and/or dimethylformamide. 
Asn(Xan) was coupled in the presence of a 1.5-fold excess of 1-hydroxyben- 
zotriazole. Hypro(Bzl) was coupled using (benzotriazol-l-yl-oxy)-tris(di- 
methylamino)-phosphonium hexafluoro-phosphate. Deblocking of the Boc 
group was accomplished with 50% TFA in DCM in the presence of 1%
1,2-ethanedithiol for 20 min. The peptido-resin (4.5 g) was treated with 
hydrofluoric acid containing anisole (10% v/v) and methylethylsulfide (5% 
v/v) for 0.5 h at — 20°C and 1.0 h at 0°C to yield the fully deprotected peptide, 
which precipitated in ether. The peptide was separated from the cleaved resin 
by filtration after dissolution in 40% acetic acid.
Peptide cyclization and biochemical characterization. The aA-OIVB 
peptide extract was poured into 4.5 I. of 0.1 m ammonium acetate, and 
the pH was adjusted to 7.75 with ammonium hydroxide. The solution 
was stirred in an open beaker, slowly in the cold room. The air oxidation 
was monitored qualitatively by the Ellman test (Ellman, 1959) and HPI.C 
(loss of absorbance ofthe starting material). Cyclization was determined 
to be complete after 3 d, whereupon the pH was lowered to 5.0 with acetic 
acid (AcOH). The solution was loaded onto 100 ml of packed BioRex 70 
beads (H"” form) in a 25 X 200 mm column, and the resin was washed 
with 100 ml of 5% AcOH; the peptide was then eluted from the resin with 
50% AcOH. The peptide-containing fractions were combined, shell fro­
zen, and lyophilized to yield 1.5 g of crude aA-OIVB. The crude peptide 
was loaded to a preparative HPI.C (Miller and Rivier, 1996) cartridge 
(5 X 30 cm) packed in the laboratory with reversed-phase 300 A Grace 
Vydac (Hesperia, CA) C1S silica (15-20 /urn particle size). The aA-OIVB 
peptide eluted with a flow rate of 100 ml/min using a binary solvent 
system with a linear gradient of 0.3% solvent B per minute [solvent A,
0.25N triethylammonium phosphate (TEAP), pH 2.25; solvent B, 60% 
ACN and 40% TEAP). Desired fractions were subjected to a second 
purification step using TEAP, pH 6.5, in a similar manner. The pH of 
purified fractions was adjusted to 2.5 with TFA, and the peptide-TEAP 
salt was exchanged to TFA using 0.1% TFA/ACN in the binary solvent 
system. The peptide at this step contained two components detected by 
capillary zone electrophoresis (CZE) using a previously described proto­
col (Miller and Rivier, 1998). The mixture was separated by ion exchange 
chromatography on an Amersham Biosciences (Arlington Heights, II.) 
Mono S 16/10 column (1.6 X 10 cm; 10 fim  particle size) using sodium 
chloride gradients in 10 nui sodium acetate (20% acetonitrile/80% wa­
ter) at pH 5.0 and was desalted by HPI.C using a gradient of ACN in 0.1% 
TFA. The desired component was determined by coelution with native 
aA-OIVB. Analytical HPI.C screening ofthe purified fractions was per­
formed on a Grace Vydac Cls column (0.46 X 25 cm; 5 f i m  particle size; 
300 A pore size) and an aqueous 0.1% TFA/ACN solvent system. The 
fractions containing aA-OIVB were pooled and lyophilized; the final 
yield was 29 mg. A comigration experiment of native and synthetic aA- 
OIVB was performed using CZE as described previously (Rivier, 2002) 
and as shown in Figure 2.
Equipment. Synthesis was performed using a Beckman Instruments 
(Fullerton, CA) System 990 Synthesizer. HPI.C equipment for purifica­
tion of synthetic peptide consisted of a PerkinElmer Life Sciences Series 
410 Liquid Chromatograph and Waters Prep 500, Waters PrepPak 1000, 
and Waters 450 Detector set at 220 nm. Ion exchange chromatography 
was performed on an Amersham Biosciences FPI.C system. Native peptide 
was purified on an Agilent (Palo Alto, CA) 1090 Liquid Chromatograph.
Biological assays. aA-OIVB was tested by intramuscular injection of 
goldfish and intraperitoneal injection of 19-d-old Swiss Webster mice. 
a-Conotoxin MI (a-MI) was injected in the same manner to serve as a 
positive control and to provide comparisons of potency with aA-OIVB. 
Injections of 0.9% NaCl served as negative controls. For each injection, 
the toxin was diluted in 0.9% NaCl solution. Animals were observed for 
behavioral effects for a minimum of 3 h after injection.
Electrophysiology. To express each receptor, cRNA was prepared and 
injected into Xenopus oocytes as described previously (Cartier et al, 
1996). Oocytes were injected 1-2 d after harvesting and used for voltage- 
clamp recording 2 -6  d after injection.
Voltage-clamp recording was done as described previously (Cartier et 
al, 1996). Briefly, oocytes were clamped at —70 mV with a two-electrode 
system and perfused with ND96 containing 1 /um atropine to block en­
dogenous muscarinic acetylcholine receptors and 0.2 mg/ml bovine se­
rum albumin to reduce nonspecific adsorption of toxin. ND96 consisted 
of 96 itim NaCl, 2.0 nui KCL, 1.8 mw CaCl,, 1.0 nui MgCl,, and 5 mw 
HEPES, pH 7.1-7.5. Acetylcholine (ACh)-gated currents were elicited by 
the following concentrations of ACh: 1 or 2 /um for the human neuro­
muscular nAChR subtypes (a lfileB  or aipiyfi-subunits); and 100 /um 
for all neuronal nAChR subtypes. A 1 s pulse of ACh was applied to 
oocytes at a frequency of once per minute in each case.
To obtain dose-response curves and IC,„ values, a minimum of five 
different concentrations of peptide toxin were applied to a given oocyte 
in a static bath (30 /ul volume). Three different oocytes were tested to 
obtain a dose-response curve. The peptide was allowed to equilibrate 
with the receptors expressed in the oocytes for 5 min before pulsing with 
ACh. To establish that a peptide did not target a particular receptor, the 
peptide was tested at a concentration of 100 /um on at least two different 
oocytes expressing the particular receptor.
Dose-response curves were fit to the following equation: % Re­
sponse =  100/{ 1 +  ([toxin)/ICs0)«H}, where «H is the Hill coefficient 
(GraphPad Software, San Diego, CA).
R esults
Purification of native aA-OIVB
The m arine snail from  which aA-OIVB was purified, C. obscurus, 
is relatively small ( ~ 1  cm ), with m iniscule am ounts o f venom  in 
each duct (typically <JC0.5 /ml). To m inim i/,eharvesting wild spec­
im ens, the venom  from  specim ens kindly donated  to  us (by Wes 
T ho rsson  and  Ray M cK insey) was ob ta in ed  by m ilk ing  as 
described in M ateria ls and  M ethods. Because o f th e  severely 
lim iting  am o u n ts  o f  venom  available, m ajo r co m p o n en ts  o f 
the venom  w ere purified  w ith o u t any b iological o r  b io ch em i­
cal assays and  w ere d irectly  sequenced. W herever possible, the 
pep tides w ere then  chem ically synthesized and  folded, and  
fu rth e r functional ch aracteriza tion  was perfo rm ed  w ith syn­
thetic  p ep tide  to spare  harvesting  m ore  C. obscurus specim ens 
from  th e  wild.
Native aA-OIVB was isolated and  purified from  m ilked C. 
obscurus venom  as show n in Figure 1 and  described in M aterials 
and M ethods. The m ajor peak, identified by the arrow  in Figure 
1 R, was sequenced by F.dman deg radation  to  yield th e  am ino  
acid  sequence  C C G V O N A A C PO C V C N K T C G , w here O  is 
hydroxyproline. The average mass (1866.5) obtained for the pep ­
tide is consistent with an am idated C term inus and the sequence 
C CG V O N A A CPO C V C N K TC G -N II,. This pep tide shares the 
same cysteine pattern  as previously characterized aA -conotoxins 
(H opkins et al., 1995; Jacobsen et al., 1997; Teichert e ta l., 2004). 
Because o fth e  shared cysteine pattern  and  subsequent character­
ization, we designated the peptide aA-OIVB.
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Figure 1. Purification of aA-OIVB .A, Milked venom was fractionated on a reversed-phase Cg 
HPLC column J , Further purification of thefraction marked by an arrow in^ provided aA-OIVB 
as the major peak, also marked by an arrow in B.
Chemical synthesis and biochemical characterization 
of aA-OIVB
aA-OIVB was synthesized as described in M aterials and  M eth­
ods. A com igration experim ent o f native and synthetic aA-OIVB 
was perform ed using CZE. A com bined equal am oun t o f both 
synthetic and  native aA -OIVB eluted as a single symmetrical 
absorbance, shown in Figure 2. Fast atom  bom bardm ent mass 
spectrom etry for aA-OIVB gave a m onoisotopic mass o f (M +  
I I ) + m /z =  1864.71; calculated (M +  I I ) + m /z =  1864.67. 
A m ino acid analysis resulted in the expected ratios. W e conclude 
from these experim ents tha t synthetic and native aA-OIVB are 
chemically identical. A liquots o f aA -OIVB were quantified by 
am ino acid analysis to ensure accuracy o f results for biological 
and electrophysiological assays. Synthetic aA-OIVB was used for 
subsequent experim ents.
Biological assays
aA-OIVB was assayed by in tram uscular injection o f goldfish. 
T he toxin reproducibly caused a delayed b u t com plete paralysis 
in goldfish at a concentration  o f 0.5 nrnol/g, in contrast to the 
absence of any observable effect when goldfish were injected with 
saline solution alone. Partial paralysis and im paired sw im m ing 
were observed when lower concentrations o f aA -OIVB were 
used. Goldfish tha t did no t die from the toxin-induced paralysis 
recovered and  resum ed sw im m ing within the 5 h postinjection 
observation period.
The peptide was also injected into mice; even at doses >  1 
nrnol/g, no obvious behavioral o r paralytic effects were observed.
Electrophysiology: specificity of aA-OIVB for the 
mammalian fetal muscle nAChR
aA-OIVB was tested on Xenopus oocytes expressing either the 
hum an  fetal ( a l [31 yfi-subunits) o r adult (al/31efi-subunits) 
neurom uscular nA C hR by tw o-electrode voltage clam ping, using
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Figure 2. Comigration of synthetic and native aA-OIVB using CZE (100 mM Na2FIP04 buffer 
at pFI 2.5 and a voltage of 15 kV). AUFS, Absorbance units full scale.
a static-bath application o f toxin. aA -OIVB potently  inhibited 
the fetal m uscle nAChR (a l  f3l yfi-subunits) with > l8 0 0 -fo ld  
higher affinity than its inhibition  o f the adult m uscle nAChR 
(a l  f} \efi-subunits) (Fig. 3).
The high-affinity block o f the fetal m uscle nA ChR by aA - 
OIVB (IC50 of 56 nM) is in contrast to its low affinity for a num ber 
of additional nicotinic acetylcholine receptors. W e tested aA - 
OIVB on Xenopus oocytes expressing various neuronal nAChR 
subtypes to better define its targeting specificity. At a concen tra­
tion o f 100 /mM, aA-OIVB did no t significantly block m ost o f the 
receptors tested. In all cases, at a concentration  o f 100 /mM, aA - 
OIVB blocked < 5 0 %  o f elicited response for each receptor tested, 
with the exception o f the hum an fetal m uscle nAChR, which it 
blocked completely. These experim ents attest to the targeting 
specificity o f aA -OIVB for the fetal subtype o f the neurom uscular 
nAChR (Fig. 4).
Discussion
aA-OIVB, purified from the venom  o f C. obsatnts, has >  1800­
fold higher affinity for the hum an fetal m uscle nAChR than the 
hum an  adult m uscle nAChR. aA -OIVB does no t target various 
neuronal nAChRs; thus, it appears to be  a specific inh ib ito r o f the 
fetal m uscle nAChR. The toxin causes a reversible neurom uscular 
paralysis after injection into goldfish.
A lthough num erous inhib itors o f the neurom uscular nAChR 
have been characteri7,ed previously, none have proven to share 
with aA-OIVB the b ind ing  specificity for the fetal subtype o f the 
m am m alian m uscle nAChR. a-B ungaro tox in  and num erous 
snake a -n eu ro  toxins b ind  both  the a  I S an d  a  17  interfaces of the 
m uscle receptor with high affinity. Because o f the high-affinity 
b inding o f the a lf i  interface, these are no t selective for the fetal 
m uscle nAChR. Toxins know n as wagerlins from the pit viper
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Figure 3. Dose-response of aA-OIVB on the human fetal and adult muscle nAChR by two- 
electrode voltage-damping Xenopus oocytes. Toxin was applied to oocytes in a static bath and 
allowed to equilibrate with receptors for 5 min before pulsing with ACh. aA-OIVB blocked the 
human fetal muscle nAChR (filled triangles) with an IC5I) of 56 nM (44.2-72.4 nM; 95% confi­
dence interval). In contrast, it blocked the human adult muscle nAChR (open circles) with an
Figure 4. aA-OIVB was tested for specificity as an inhibitor against multiple nicotinic ace­
tylcholine receptors by two-electrode voltage-clamping Xenopus oocytes. Toxin was applied at 
a concentration of 100 /m to oocytes in a static bath and allowed to equilibrate for 5 min before 
pulsing with ACh and resuming perfusion of ND96 buffer. The bar graph represents the peak 
amplitude response after toxin application (error bars indicate ± SEM) as a percentage of 
control responses. The inhibition of the fetal muscle nAChR (a10178-subunits) is in contrast 
to the relative lack of inhibition of various other nAChRs. H, Human clone; R, rat clone, n > 2 
oocytes for each nAChR tested.
Tritmresurus wagleri b ind  with 2000-fold higher affinity to the 
a  I e interface o f the adu lt receptor over the a  I ft and a  17  in ter­
faces (M cArdle et al., 1999), thus giving a subtype selectivity for 
neurom uscular nAChRs com plem entary to aA-OIVB. The 
a -neu ro tox in  NrnniT from  Naja rnossarnbica rnossarnbica b inds 
bo th  the a  IS- and a  17 -subun it interfaces with ~  1000-fold 
higher affinity than the a  1 e interface (Osaka et al., 1999). C urare 
and o ther curariform  antagonists b ind  w ith relatively high affin­
ity to bo th  the a  1 e and a  1 7  interfaces o f the m am m alian muscle 
nAChR, whereas they b ind  w ith ~  100-fold lower affinity to the
a lf i  interface (Sine, 1993; Bren and Sine, 1997). Many o f the 
a-cono tox ins b ind  w ith 10,000-fold higher affinity to the m am ­
m alian a  1 ft interface than  the a  17  interface (G roebe et al., 1995), 
whereas aA -conotoxins F.IVA and F.IVB block bo th  the a  1 ft and 
a l  7  interfaces with equal affinity (Jacobsen et al., 1997). N otably 
absent am ong previously characterized antagonists o f  the n eu ro ­
m uscular nAChR are those tha t selectively inh ib it the fetal muscle 
nAChR (a  lj317 ft-subunits), i.e., antagonists tha t b ind  the a  1 7 - 
subunit interface preferentially over the a  1 ft and a  1 e interfaces o f 
the adu lt form  o f  the m uscle receptor ( a l  j31efi-subunits).
Thus, aA -OIVB, w ith its selectivity for the fetal muscle 
nAChR versus the adu lt m uscle nAChR, fills the gap in specificity 
am ong various inhibitors o f the nAChR. A lthough expression of 
the 7 -subun it o f the nAChR in m am m als is prim arily in fetal 
m uscle tissue, there are instances o f 7 -subuni t expression in adult 
tissues, i.e., thym us and extraocular m uscle fibers under norm al 
conditions, and m uscle tissue under various pathological condi­
tions (Gu and  I Tall, 1988; Marx et al., 1989; W itzem ann et al., 
1989; H orton  et al., 1993; N avaneetham  et al., 2001; G attenloeh­
ner et al., 2002). T he physiological role o f  the fetal m uscle nAChR 
is undefined under these conditions; aA-OTVB should prove use­
ful in elucidating b o th  the norm al and pathological roles o f 
7 -subun it expression in bo th  fetal and adult m am m als. Thus, the 
peptide provides a potential tool for inhibiting function o f  the 
fetal nAChR w ithout d isrupting  its assembly and w ithout dis­
rupting  the function  or expression o f  the adult neurom uscular 
nAChR.
The sequences o f the know n aA -conotoxins are the following: 
aA-EIVA, CCCGPYONAACTIOCCCKVCROOYCDROSCC# 
aA-ETVB, CCCGKYONAACTIOCCCTVCROOYCDROSCC#: 
aA-PTVA, CCCGSYONAACTIOCSCKDROSYCCQ#; and aA - 
OIVA, CCGVONAACTIOCVCKNTC#; aA-OTVB, CCGVONA- 
ACPOCVCNKTCG#, where O  indicates hydroxyproline, and # in­
dicates amidation.
The subtype selectivity o f aA-PTVA has no t been analyzed. 
aA-OTVA was identified previously only as a low-affinity inh ib­
itor o f the adult ( a l  j31 efi) m uscle nAChR (Teichert et al., 2004). 
A dditional characterization o f aA-OTVB, aA-OTVA, and aA - 
PTVA has been initiated, including structu re-function  studies 
and a detailed analysis o f  the kinetics.
A lthough it may seem odd  that a peptide from Conns venom 
targets specifically a fetal receptor as opposed to an adult recep­
tor, a recent report on nicotinic acetylcholine receptors in puff- 
erfish (Fngn nibripes) indicates tha t hom ologs o f bo th  the m am ­
m alian 7 - and e-subunits are expressed in m uscle and gill in 
im m ature adult pufferfish, before full differentiation o f sex o r­
gans (Jones et al., 2003). Thus, the fact tha t aA-OTVB was found 
in the venom o f a fish-hunting Conns species can be  rationalized 
if som e o f  their fish prey express bo th  7 - and e-subunits sim ulta­
neously in m uscle and gill; this m ay explain the evolution o f a 
conotoxin targeted to 7 -subunit-con tain ing  receptors.
The specificity o f aA-OTVB for the a  1 7 -subun it interface of 
nAChRs confers an interesting phylogenetic profile o f  activity 
com pared w ith o ther antagonists o f  neurom uscular nAChR sub­
types. W e injected a-MT as a control when we perform ed the 
biological assays with aA-OTVB; a-MT is highly specific for the 
a lf i-su b u n it interface (Sine et al., 1995). As expected, a-MT elic­
ited paralysis in goldfish (at a dose o f ~ 0 .030  nrnol/g under the 
conditions used) b u t was even m ore p o ten t when injected into 
mice (—0.013 nrnol/g). Tn contrast, aA-OTVB paralyzed goldfish 
b u t elicited no obvious paralytic sym ptom s in mice, even when 
higher doses (up to >  1 nrnol/g) were used. However, aA-OTVB 
causes a high-affinity block o f  bo th  hum an a  1 j317 ft receptors (as
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described above), as well as the hom ologous cloned roden t recep­
to r (results no t show n). Thus, it may be possible to use the pep­
tide to assess effects o f blocking y-contain ing receptors in the 
thym us on the im m une system in vivo, because the peptide does 
no t paralyze the adult animal.
There are potential biom edical applications for the peptide, 
for example, the discovery that the fetal form  of the muscle 
nAChR is expressed in rhabdom yosarcom a, a com m on form  of 
pediatric soft-tissue sarcom a. The y-subun it o f the muscle 
nAChR has been proposed as a diagnostic m arker for this form  of 
cancer because it differentiates betw een rhabdom yosarcom a and 
o ther tum ors, as well as norm al tissue. The fetal form  o f the 
m uscle nAChR has also been suggested as a possible d rug target 
for rhabdom yosarcom a (G attenloehner et al., 1998, 1999). Thus, 
aA-OIVB should be a useful ligand that has diagnostic and ther­
apeutic potential, as well as a clear role for addressing questions 
regarding y-subunit-contain ing  nAChRs.
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